Clinical switching patterns and reasons between bevacizumab biosimilar and originator drugs
- VernacularTitle:贝伐珠单抗生物类似药与原研生物药的临床转换模式及转换原因分析
- Author:
Min OU
1
;
Yaqin WANG
2
;
Zhimin ZHU
3
;
Fangfang ZHANG
4
;
Qiongni ZHU
1
Author Information
1. Dept. of Pharmacy，Ruijin Hospital，Shanghai Jiao Tong University School of Medicine，Shanghai 200025，China
2. Dept. of Pharmacy，Henan Provincial People’s Hospital，Zhengzhou 450003，China
3. Dept. of Pharmacy，Shanghai Eighth People’s Hospital，Shanghai 200235，China
4. Dept. of Pharmacy，Qinghai Oilfield Hospital，Gansu Dunhuang 736202，China
- Publication Type:Journal Article
- Keywords:
bevacizumab;
originator drugs;
biosimilar;
drug switching;
safety;
adverse reaction;
accessibility
- From:
China Pharmacy
2025;36(18):2297-2300
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To analyze clinical switching patterns and reasons between bevacizumab biosimilar and originator drugs. METHODS The data were collected from 1 175 cancer patients treated with bevacizumab at Ruijin Hospital， Shanghai Jiao Tong University School of Medicine from January 1， 2018， to December 31， 2023. The patients were divided into originator group （n＝250） and biosimilar group （n＝925）. The switching rate， switching type and reasons of the two groups were compared. RESULTS There were no statistically significant differences in the switching rate， switching types， and the number of switches between the two groups （P＞0.05）. Single， one-way switches were the switching type in both groups. The proportion of patients in the biosimilar group who switched due to adverse events was significantly higher than originator group， while the proportion of patients who switched due to treatment costs was significantly lower than originator group （P＜0.05）. There were no statistically significant differences in the proportions of patients who switched due to efficacy and drug accessibility between the two groups （P＞0.05）. CONCLUSIONS The switching between bevacizumab biosimilar and the originator drugs mainly involves single， one- way switches. Treatment costs and drug accessibility are the main factors for the switches among users of originator drugs， while drug accessibility and adverse events are the main factors for the switches among users of biosimilar.
